Long-term survival of patients with multiple sclerosis in West France

Multiple Sclerosis

Volumn 13, Issue 7, 2007, Pages 865-874

  Leray, E ^a   Morrissey, Sean Patrick ^a,c   Yaouang, J ^a   Coustans, M ^a   Le Page, E ^a   Chaperon, J ^b   Edan, G ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c CAMPUS DE BEAULIEU   (France)

Author keywords

Multiple sclerosis; Standardized mortality rates; Survival

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; METHOTREXATE; MITOXANTRONE;

ADULT; ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FEMALE; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PROGNOSIS; RELAPSE; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; AGED; CAUSE OF DEATH; DISABILITY; KAPLAN MEIER METHOD; MIDDLE AGED;

ADULT; AGED; CAUSE OF DEATH; DISABILITY EVALUATION; FEMALE; FRANCE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROGNOSIS;

EID: 35848934337     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507077410     Document Type: Article

References (45)

1. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W. Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989; 112: 133-46.
2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-82.
3. Percy AK, Nobrega Fr, Okazaki H, Glattre E, Kurland LT. Multiple sclerosis in Rochester, Minn. A 60-year appraisal. Arch Neurol 1971; 25: 105-11.
4. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987; 14: 255-61.
5. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990; 113: 1597-628.
6. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. J Neurol Neurosurg Psychiatry 1987; 50: 523-31.
7. Riise T. Gronning M, Aarli JA, Nyland H, Larsen JP, Edland A. Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models. J Clin Epidemiol 1988; 41: 1031-36.
8. Poser S, Kurtzke JF, Poser W, Schlaf G. Survival in multiple sclerosis. J Clin Epidemiol 1989; 42: 159-68.
9. Sadovnick AD, Ebers GC, Wilson RW, Paty DW. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992; 42: 991-94.
10. Bronnum-Hansen H, Koch-Henriksin N, Hyllested K. Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 1994; 44: 1901-907.
11. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127: 844-50.
12. Kantarci O, Siva A, Eraksoy M. Karabudak R. Sutlas N, Agaoglu J et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51: 765-72.
13. Cottrell DA, Kremenchutzky M, Rice GP, Hader W, Baskerville J. Ebers GC. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122: 625-39.
14. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler 1999; 5: 293-96.
15. Levic ZM, Dujmovic I, Pekmezovic T, Jarebinski M, Marinkovic J, Stojsavljevic N et al. Prognostic factors for survival in multiple sclerosis. Mult Scler 1999; 5: 171-78.
16. Wallin MT, Page WF, Kurtzke JF. Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain 2000; 123: 1677-87.
17. Kurtzke JF, Heltberg A. Multiple sclerosis in the Faroe Islands: an epitome. J Clin Epidemiol 2001; 54: 1-22.
18. Sumelahti ML, Tienari PJ, Wikstrom J, Salminen TM, Hakama M. Survival of multiple sclerosis in Finland between 1964 and 1993. Mult Scler 2002; 8: 350-55.
19. Phadke JG, Downie AW. Epidemiology of multiple sclerosis in the north-east (Grampian region) of Scotland - an update. J Epidemiol Community Health 1987; 41: 5-13.
20. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193-96.
21. Miller DH, Hornabrook RW, Purdie G. The natural history of multiple sclerosis: a regional study with some longitudinal data. J Neurol Neurosurg Psychiatry 1992; 55: 341-46.
22. Midgard R, Albrektsen G, Riise T, Kvale G, Nyland H. Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995; 58: 417-21.
23. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998; 65: 56-59.
24. Pekmezovic T, Jarebinski M, Drulovic J, Stojsavljevic N, Levic Z. Survival of multiple sclerosis patients in the Belgrade population. Neuroepidemiology 2002; 21: 235-40.
25. Pittock SJ, Mayr WT. McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004; 62: 51-59.
26. Kurtzke JF, Beebe GW, Nagler B, Nefzger MD, Auth TL, Kurland LT. Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. Arch Neurol 1970; 22: 215-25.
27. Malmgren RM, Dudley JP, Visscher BR, Valdiviezo NL, Clark VA, Detels R. Mortality in persons with multiple sclerosis in the Seattle and Los Angeles areas. JAMA 1981; 246: 2042-45.
28. Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota. Neurology 1990; 40: 780-86.
29. Ebers GC. Natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71(Suppl 2): ii16-19.
30. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995; 13: 119-46.
31. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-76.
32. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
33. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
34. Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowellF et al. Problems of experimental trials of therapy in multiple sclerosis: Report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann N Y Acad Sci 1965; 122: 552-68.
35. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
36. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972; 34: 187-220.
37. Statistical Package for Social Science [program]. SPSS, 2002.
38. Burr ML. Explaining the French paradox. J R Soc Health 1995; 115: 217-19.
39. Poser S, Poser W, Schlaf G, Firnhaber W, Lauer K, Wolter M et al. Prognostic indicators in multiple sclerosis. Acta Neurol Scand 1986; 74: 387-92.
40. Riise T, Gronning M, Fernandez O, Lauer K, Midgard R, Minderhoud JM et al. Early prognostic factors for disability in multiple sclerosis, a European multicenter study. Acta Neurol Scand 1992; 85: 212-18.
41. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116: 117-34.
42. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352: 1491-97.
43. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56: 1496-504.
44. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-87.
45. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-95.